Atlas Trials

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Clinical trial NCT04270747 · COMPLETED

Trial details

NCT number
NCT04270747
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Start date
2020-06-22
Primary completion
2022-07-18
Enrollment
576

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.